PTGS2 and hepatocellular carcinoma: Lee et al. supposed that the combination between simvastatin and NS398, a COX-2 inhibitor, could maximize pharmacological efficacy and may minimize adverse effects in HCC exhibiting a synergistic effect in Hep3B and Huh-7 cell lines.